KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Total Liabilities (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Total Liabilities for 17 consecutive years, with $3.1 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 11.74% to $3.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.1 billion through Dec 2025, up 11.74% year-over-year, with the annual reading at $3.1 billion for FY2025, 11.74% up from the prior year.
  • Total Liabilities for Q4 2025 was $3.1 billion at Bio-Rad Laboratories, up from $3.0 billion in the prior quarter.
  • The five-year high for Total Liabilities was $4.6 billion in Q3 2021, with the low at $2.8 billion in Q4 2024.
  • Average Total Liabilities over 5 years is $3.5 billion, with a median of $3.5 billion recorded in 2021.
  • The sharpest move saw Total Liabilities soared 44.6% in 2021, then dropped 21.99% in 2022.
  • Over 5 years, Total Liabilities stood at $4.1 billion in 2021, then decreased by 5.54% to $3.9 billion in 2022, then fell by 8.45% to $3.6 billion in 2023, then fell by 21.45% to $2.8 billion in 2024, then grew by 11.74% to $3.1 billion in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $3.1 billion, $3.0 billion, and $3.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.